MAFG also can play a role as a molecular biomarker for tumor-targeted therapy to relieve cisplatin resistance of tumor cancer cells, improving therapeutic and prognostic efficiency (Vera-Puente et al., 2018). The gene discussed is MAFG; the disease is neoplasm.